Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Calcium. 2006 Apr;16(4):665-69.

[Treatment of malignancy-associated hypercalcemia].

[Article in Japanese]

Author information

  • 1University of Tokushima, Graduate School Institute of Health Biosciences, Department of Medicine and Bioregulatory Sciences.

Abstract

Malignancy-associated hypercalcemia (MAH) is caused by tumor over-production of parathyroid hormone-related protein (PTHrP), or by locally enhanced bone resorption in metastatic lesions of solid cancers. Medical treatment of MAH includes hydration by saline infusion, loop diuretics to promote urinary calcium excretion and anti-resorptives such as calcitonin and bisphosphonates. Particularly, bisphosphonates are the current mainstay for MAH treatment : they not only inhibit osteoclastic bone resorption to ameliorate hypercalcemia but can also alleviate bone pain and can even prevent cancer cell expansion in bone metastatic lesions.

PMID:
16582519
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk